{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:07:12Z","timestamp":1787695632398,"version":"build-2784847793"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2023-I2M-C&T-B-039"],"award-info":[{"award-number":["2023-I2M-C&T-B-039"]}]},{"name":"National Key R&D Program of China, Ministry of Science and Technology of the People's Republic of China","award":["2022YFC2407100, 2022YFC2407101"],"award-info":[{"award-number":["2022YFC2407100, 2022YFC2407101"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"DOI":"10.1186\/s13014-025-02688-7","type":"journal-article","created":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T18:29:18Z","timestamp":1752690558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Moderately hypofractionated online adaptive radiotherapy (SWIFT-1) in cervical cancer patients: study protocol for a multi-centered, open-label, two-arm, phase III, randomized controlled study"],"prefix":"10.1186","volume":"20","author":[{"given":"Zheng","family":"Zeng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yining","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyin","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuliang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8785-9948","authenticated-orcid":false,"given":"Junfang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1079-5137","authenticated-orcid":false,"given":"Ke","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6856-2320","authenticated-orcid":false,"given":"Fuquan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,16]]},"reference":[{"issue":"3","key":"2688_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"issue":"15","key":"2688_CR2","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","volume":"340","author":"P Rose","year":"1999","unstructured":"Rose P, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. New Engl J Med. 1999;340(15):1144\u201353.","journal-title":"New Engl J Med"},{"key":"2688_CR3","unstructured":"Network NCC. NCCN Clinical Practice Guidelines in Oncology: Cervical Cancer. 2025; Version 1."},{"key":"2688_CR4","doi-asserted-by":"publisher","first-page":"e070115","DOI":"10.1136\/bmj-2022-070115","volume":"379","author":"L Rahangdale","year":"2022","unstructured":"Rahangdale L, Mungo C, O\u2019Connor S, Chibwesha CJ, Brewer NT. Human papillomavirus vaccination and cervical cancer risk. BMJ. 2022;379:e070115.","journal-title":"BMJ"},{"issue":"2","key":"2688_CR5","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/j.ijrobp.2019.01.091","volume":"104","author":"I Abu-Gheida","year":"2019","unstructured":"Abu-Gheida I, Reddy CA, Kotecha R, et al. Ten-Year outcomes of moderately hypofractionated (70 Gy in 28 fractions) intensity modulated radiation therapy for localized prostate Cancer. Int J Radiat Oncol Biol Phys. 2019;104(2):325\u201333.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2688_CR6","doi-asserted-by":"publisher","first-page":"716","DOI":"10.3390\/curroncol28010070","volume":"28","author":"HL Yaremko","year":"2021","unstructured":"Yaremko HL, Locke GE, Chow R, Lock M, Dinniwell R, Yaremko BP. Cost minimization analysis of hypofractionated radiotherapy. Curr Oncol. 2021;28(1):716\u201325.","journal-title":"Curr Oncol"},{"issue":"34","key":"2688_CR7","doi-asserted-by":"publisher","first-page":"JCO1801097","DOI":"10.1200\/JCO.18.01097","volume":"36","author":"SC Morgan","year":"2018","unstructured":"Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA Evidence-Based guideline. J Clin Oncol. 2018;36(34):JCO1801097.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2688_CR8","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S1470-2045(21)00539-8","volume":"23","author":"I Meattini","year":"2022","unstructured":"Meattini I, Becherini C, Boersma L, et al. European society for radiotherapy and oncology advisory committee in radiation oncology practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer. Lancet Oncol. 2022;23(1):e21\u201331.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2688_CR9","first-page":"127","volume":"39","author":"MA Muckaden","year":"2002","unstructured":"Muckaden MA, Budrukkar AN, Tongaonkar HB, Dinshaw KA. Hypofractionated radiotherapy in carcinoma cervix IIIB: Tata memorial hospital experience. Indian J Cancer. 2002;39(4):127\u201334.","journal-title":"Indian J Cancer"},{"issue":"3","key":"2688_CR10","doi-asserted-by":"publisher","first-page":"S89","DOI":"10.1016\/j.ijrobp.2022.07.500","volume":"114","author":"A Gandhi","year":"2022","unstructured":"Gandhi A, Rastogi M, Yadav U, et al. A pilot study of moderately hypo-fractionated whole pelvic radiotherapy with concurrent chemotherapy and image-guided high dose rate brachytherapy for locally advanced cervical carcinoma. Int J Radiat Oncol Biol Phys. 2022;114(3):S89.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2688_CR11","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.radonc.2022.09.015","volume":"176","author":"LM Astrom","year":"2022","unstructured":"Astrom LM, Behrens CP, Storm KS, Sibolt P, Serup-Hansen E. Online adaptive radiotherapy of anal cancer: normal tissue sparing, target propagation methods, and first clinical experience. Radiother Oncol. 2022;176:92\u20138.","journal-title":"Radiother Oncol"},{"issue":"1","key":"2688_CR12","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13014-023-02394-2","volume":"19","author":"G Wang","year":"2024","unstructured":"Wang G, Wang Z, Guo Y, et al. Evaluation of PTV margins with daily iterative online adaptive radiotherapy for postoperative treatment of endometrial and cervical cancer: a prospective single-arm phase 2 study. Radiat Oncol. 2024;19(1):2.","journal-title":"Radiat Oncol"},{"key":"2688_CR13","first-page":"100596","volume":"40","author":"CE Shelley","year":"2023","unstructured":"Shelley CE, Bolt MA, Hollingdale R, et al. Implementing cone-beam computed tomography-guided online adaptive radiotherapy in cervical cancer. Clin Transl Radiat Oncol. 2023;40:100596.","journal-title":"Clin Transl Radiat Oncol"},{"issue":"7","key":"2688_CR14","doi-asserted-by":"publisher","first-page":"101510","DOI":"10.1016\/j.adro.2024.101510","volume":"9","author":"G Wang","year":"2024","unstructured":"Wang G, Wang Z, Zhang Y, et al. Daily online adaptive radiation therapy of postoperative endometrial and cervical Cancer with PTV margin reduction to 5\u00a0mm: dosimetric outcomes, acute toxicity, and first clinical experience. Adv Radiat Oncol. 2024;9(7):101510.","journal-title":"Adv Radiat Oncol"},{"key":"2688_CR15","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1016\/j.ijrobp.2024.07.014","volume":"120","author":"Z Zeng","year":"2024","unstructured":"Zeng Z. Yan. Moderated hypofractionated online adaptive radiotherapy in locally advanced cervical cancer: A prospective 1 clinical trial. Int J Radiat Oncol Biol Phys. 2024;120:S17\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"2688_CR16","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/S1470-2045(23)00147-X","volume":"24","author":"LR Mileshkin","year":"2023","unstructured":"Mileshkin LR, Moore KN, Barnes EH, et al. Adjuvant chemotherapy following chemoradiotherapy as primary treatment for locally advanced cervical cancer versus chemoradiotherapy alone (OUTBACK): an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24(5):468\u201382.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2688_CR17","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ygyno.2018.09.024","volume":"151","author":"W Wang","year":"2018","unstructured":"Wang W, Zhang F, Hu K, Hou X. Image-guided, intensity-modulated radiation therapy in definitive radiotherapy for 1433 patients with cervical cancer. Gynecol Oncol. 2018;151(3):444\u20138.","journal-title":"Gynecol Oncol"},{"issue":"10","key":"2688_CR18","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1007\/s12094-023-03151-3","volume":"25","author":"Z Zeng","year":"2023","unstructured":"Zeng Z, Wang W, Liu X, et al. Optimal cisplatin cycles in locally advanced cervical carcinoma patients treated with concurrent chemoradiotherapy. Clin Transl Oncol. 2023;25(10):2892\u2013900.","journal-title":"Clin Transl Oncol"},{"issue":"2","key":"2688_CR19","doi-asserted-by":"publisher","first-page":"e176","DOI":"10.1016\/j.prro.2022.10.009","volume":"13","author":"A Yen","year":"2023","unstructured":"Yen A, Choi B, Inam E, et al. Spare the bowel, don\u2019t spoil the target: optimal margin assessment for online cone beam adaptive radiation therapy (OnC-ART) of the cervix. Pract Radiat Oncol. 2023;13(2):e176\u201383.","journal-title":"Pract Radiat Oncol"},{"issue":"3","key":"2688_CR20","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.ijrobp.2013.06.2059","volume":"87","author":"AK Gandhi","year":"2013","unstructured":"Gandhi AK, Sharma DN, Rath GK, et al. Early clinical outcomes and toxicity of intensity modulated versus conventional pelvic radiation therapy for locally advanced cervix carcinoma: a prospective randomized study. Int J Radiat Oncol Biol Phys. 2013;87(3):542\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"2688_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.ijrobp.2010.06.003","volume":"80","author":"N Tyagi","year":"2011","unstructured":"Tyagi N, Lewis JH, Yashar CM, et al. Daily online cone beam computed tomography to assess interfractional motion in patients with intact cervical cancer. Int J Radiat Oncol Biol Phys. 2011;80(1):273\u201380.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2688_CR22","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1080\/0284186X.2022.2048070","volume":"61","author":"W Bacorro","year":"2022","unstructured":"Bacorro W, Baldivia K, Dumago M, et al. Phase 1\/2 trial evaluating the effectiveness and safety of dose-adapted hypofractionated pelvic radiotherapy for advanced cervical cancers ineligible for chemotherapy (HYACINCT). Acta Oncol. 2022;61(6):688\u201397.","journal-title":"Acta Oncol"},{"key":"2688_CR23","doi-asserted-by":"crossref","unstructured":"Wang G, Chen Y, Wang Z et al. A prospective Single-Arm study of daily online adaptive radiation therapy for cervical Cancer with reduced planning target volume margin: acute toxicity and dosimetric outcomes. Int J Radiat Oncol Biol Phys 2025.","DOI":"10.1016\/j.ijrobp.2025.03.051"},{"key":"2688_CR24","first-page":"48","volume":"9","author":"R Potter","year":"2018","unstructured":"Potter R, Tanderup K, Kirisits C, et al. The EMBRACE II study: the outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol. 2018;9:48\u201360.","journal-title":"Clin Transl Radiat Oncol"},{"key":"2688_CR25","doi-asserted-by":"crossref","unstructured":"Hodapp N, [The ICRU. Report 83: prescribing, recording and reporting photon-beam intensity-modulated radiation therapy (IMRT)]. Strahlenther Onkol. 2012;188(1):97\u20139.","DOI":"10.1007\/s00066-011-0015-x"},{"issue":"10434","key":"2688_CR26","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(24)00317-9","volume":"403","author":"D Lorusso","year":"2024","unstructured":"Lorusso D, Xiang Y, Hasegawa K, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11\/GOG-3047\/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet. 2024;403(10434):1341\u201350.","journal-title":"Lancet"},{"key":"2688_CR27","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Seymour L, Litiere S, et al. RECIST 1.1 - Standardisation and disease-specific adaptations: perspectives from the RECIST working group. Eur J Cancer. 2016;62:138\u201345.","journal-title":"Eur J Cancer"},{"issue":"1","key":"2688_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.brachy.2011.07.002","volume":"11","author":"AN Viswanathan","year":"2012","unstructured":"Viswanathan AN, Beriwal S, De Los Santos JF, et al. American brachytherapy society consensus guidelines for locally advanced carcinoma of the cervix. Part II: high-dose-rate brachytherapy. Brachytherapy. 2012;11(1):47\u201352.","journal-title":"Brachytherapy"},{"issue":"5","key":"2688_CR29","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1016\/j.ijrobp.2015.12.363","volume":"94","author":"K Kirchheiner","year":"2016","unstructured":"Kirchheiner K, Potter R, Tanderup K, et al. Health-Related quality of life in locally advanced cervical Cancer patients after definitive chemoradiation therapy including image guided adaptive brachytherapy: an analysis from the EMBRACE study. Int J Radiat Oncol Biol Phys. 2016;94(5):1088\u201398.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"2688_CR30","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1001\/jamaoncol.2024.0565","volume":"10","author":"WK Cho","year":"2024","unstructured":"Cho WK, Park W, Kim SW, Lee KK, Ahn KJ, Choi JH. Postoperative hypofractionated Intensity-Modulated radiotherapy with concurrent chemotherapy in cervical cancer: the POHIM-CCRT nonrandomized controlled trial. JAMA Oncol. 2024;10(6):737\u201343.","journal-title":"JAMA Oncol"},{"issue":"3","key":"2688_CR31","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1136\/ijgc-00009577-200605000-00027","volume":"16","author":"QDM Pieterse","year":"2006","unstructured":"Pieterse QDM, ter Kuile CP, Lowik MM, van Eijkeren M, Trimbos MA, Kenter JBMZ. An observational longitudinal study to evaluate miction, defecation, and sexual function after radical hysterectomy with pelvic lymphadenectomy for early-stage cervical cancer. INT J GYNECOL CANCER. 2006;16(3):1119\u201329.","journal-title":"INT J GYNECOL CANCER"},{"issue":"7","key":"2688_CR32","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1136\/ijgc-2019-000615","volume":"29","author":"WK Cho","year":"2019","unstructured":"Cho WK, Kim YI, Park W, Yang K, Kim H, Cha H. Para-aortic lymph node recurrence after curative radiotherapy for cervical cancer. Int J Gynecol Cancer. 2019;29(7):1116\u201320.","journal-title":"Int J Gynecol Cancer"},{"issue":"8","key":"2688_CR33","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1097\/IGC.0000000000001344","volume":"28","author":"W Wang","year":"2018","unstructured":"Wang W, Liu X, Meng Q, Zhang F, Hu K. Prophylactic Extended-Field irradiation for patients with cervical Cancer treated with concurrent chemoradiotherapy: A Propensity-Score matching analysis. Int J Gynecol Cancer. 2018;28(8):1584\u201391.","journal-title":"Int J Gynecol Cancer"},{"key":"2688_CR34","first-page":"127","volume":"9","author":"MBA Muckaden","year":"2002","unstructured":"Muckaden MBA, Tongaonkar H, et al. Hypofractionated radiotherapy in carcinoma cervix IIIB: Tata memorial hospital experience. Indian J Cancer. 2002;9:127\u201334.","journal-title":"Indian J Cancer"},{"key":"2688_CR35","unstructured":"Cantu D. Phase II randomized controlled trial of concomitant chemoradiotherapy with standard fractionation compared to hypofractionated concomitant chemoradiotherapy followed by brachytherapy, for clinical stage III cervical Cancer patients (NCT04070976). 2020."},{"issue":"2","key":"2688_CR36","doi-asserted-by":"publisher","first-page":"S41","DOI":"10.1016\/j.ijrobp.2023.06.313","volume":"117","author":"T Prasartseree","year":"2023","unstructured":"Prasartseree T, Dankulchai P, Sittiwong W, Thephamongkhol K. HYPOCx-iRex (TCTR20210812003) A phase II RCT: 44 Gy\/20F VS 45 Gy\/25F CCRT in cervical cancer: Six-month Post-RT update. Int J Radiat Oncol Biol Phys. 2023;117(2):S41.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2688_CR37","unstructured":"Mendez L. Hypofractionated External-Beam radiotherapy for intact cervical Cancer (HEROICC-Trial): A feasibility study (NCT04583254) 2023."},{"key":"2688_CR38","unstructured":"Tehran University of Medical Sciences Comparison of Clinical. Response and toxicity of Hypo-Fractionated chemoradiation with standard treatment in patients with uterine cervix Cancer (NCT04831437). 2021."},{"issue":"8","key":"2688_CR39","first-page":"e66552","volume":"16","author":"Z Zeng","year":"2024","unstructured":"Zeng Z, Zhang F, Yan J. Moderated hypofractionated online adaptive radiotherapy in locally advanced cervical cancer: A case report. Cureus. 2024;16(8):e66552.","journal-title":"Cureus"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02688-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13014-025-02688-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-025-02688-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T12:45:15Z","timestamp":1757249115000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-025-02688-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,16]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2688"],"URL":"https:\/\/doi.org\/10.1186\/s13014-025-02688-7","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,16]]},"assertion":[{"value":"15 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the ethics committee at Peking Union Medical College Hospital. Protocol version 3.0 was approved on August 26, 2024. All participants should provide written informed consent prior to randomization and are free to withdraw at any time. There are no dissemination plans of this trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}